Supernus Pharmaceuticals (NASDAQ:SUPN) held its first-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.
Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more.
View the webcast at https://edge.media-server.com/mmc/p/5fevfi4v/
Summary
Supernus Pharmaceuticals reported an increase in cash, cash equivalents, and marketable securities to approximately $384 million, primarily due to cash from operations and commercial milestones, with a strong balance sheet and no debt.
The company reiterated its financial guidance for 2026, expecting total revenues between $840 million and $870 million, with R&D and SG&A expenses ranging from $620 million to $650 million, and non-GAAP operating earnings from $140 million to $170 million.
The company is addressing supply constraints for its product Anapco and expects to improve processing times and patient conversions, while maintaining guidance for Anapco revenue between $45 million and $70 million.
Zerzuve showed a healthy growth rate with an 82% increase in prescriptions year-over-year, and the company is optimistic about its market potential and ongoing DTC campaigns.
Calbri is experiencing growth, particularly in the adult market segment, with a strategy to focus on revenue-generating assets and late-stage acquisitions to continue its growth trajectory.
The company is working on bringing a second supplier online for Anapco by mid-2027, with ongoing discussions with the FDA to ensure a smooth approval process.
Full Transcript
OPERATOR
The company had approximately 384 million in cash, cash equivalents and marketable securities, compared to 309 million as of December 31, 2025. This increase was primarily due to cash generated from operations, the timing of Medicaid payments and the Shionogi related commercial milestones. The Company’s balance sheet remained strong with no debt and significant financial flexibility for potential M&A and other growth opportunities. Now turning to guidance for full year 2026, the company reiterates its financial guidance for total revenues, combined R&D and SG&A expenses, and non GAAP operating earnings. As such, we expect total revenues to range from 840 million to 870 million, comprised of commercial product revenues and royalty and licensing revenues. For the full year 2026, we expect combined R and D and SGA expenses to range from $620 million to $650 million. Overall, we expect full year operating earnings in the range of zero to $30 million. And finally, we expect non GAAP operating earnings to range from $140 million to $170 million. Please refer to the earnings press release issued prior to this call that identifies the various ranges of reconciling items between GAAP and non-GAAP. With that, I will now turn the call back over to the operator for Q and A Operator. Thank you. At this time we will conduct the question and answer session. As a reminder to ask a question, you will need to press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question comes from Andrew Tsai from Jeffries. Your …
This post was originally published here
